SCHEMBL926723

SCHEMBL926723

O=C(Nc1cnc2c(c1)CCN2)c1cc2cc(F)ccc2n1Cc1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.43
MAOB P27338 1/20 0.42
ABCB1 P08183 1/20 0.41
ECE1 P42892 5/20 0.40
CCR2 P41597 1/20 0.40
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
F2 P00734 1/20 0.37
PPARG P37231 1/20 0.37
FSCN1 Q16658 1/20 0.37
SCD O00767 1/20 0.37
ROCK1 Q13464 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1051931 0.87 F10 (0.43) F10MAOBABCB1ECE1CCR2
SCHEMBL926825 0.85 F10 (0.42) F10MAOBABCB1ECE1CCR2
SCHEMBL27829312 0.83 PIK3C3 (0.37) MAOBECE1
SCHEMBL926034 0.82 ABCB1 (0.46) F10MAOBABCB1ECE1CCR2
SCHEMBL926868 0.81 ABCB1 (0.45) F10MAOBABCB1ECE1CCR2
SCHEMBL1049583 0.81 F10 (0.41) F10MAOBABCB1ECE1CCR2
SCHEMBL927456 0.80 TNIK (0.53) F10MAOBECE1CCR2
SCHEMBL3149280 0.80 ECE1 (0.43) F10MAOBABCB1ECE1CCR2
SCHEMBL1049577 0.80 NPC1 (0.48) F10MAOBECE1CCR2PPARG
SCHEMBL3150050 0.79 PYGL (0.47) F10MAOBABCB1ECE1CCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2235015-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-24 EP claimed
US-8354425-B2 Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-15 US claimed
US-20110009364-A1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US claimed
EP-2235015-B1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-24 EP disclosed
US-8354425-B2 Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-01-15 US disclosed
CN-101977911-A Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof SANOFI AVENTIS 2011-02-16 CN disclosed
US-20110009364-A1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009364-A1 AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF ZYX, XDH, ZFX F10 1361/4885MAOB 822/4885ABCB1 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.